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Abstract No current estimates exist for the size of the
population of people who inject drugs (PWID) in the
District of Columbia (DC). The WHO/UNAIDS Guidelines
on Estimating the Size of Populations Most at Risk to HIV
was used as the methodological framework to estimate the
DC PWID population. The capture phase recruited harm
reduction agency clients; the recapture phase recruited
community-based PWID. The 951 participants were predominantly Black (83.9 %), male (69.8 %), and 40? years
of age (68.2 %). Approximately 50.3 % reported injecting
drugs in the past 30 days. We estimate approximately 8829
(95 % CI 4899 and 12,759) PWID in DC. When adjusted
for possible missed sub-populations of PWID, the estimate
increases to 12,000; thus, the original estimate of approximately 9000 should be viewed in the context of the
95 % confidence interval. These evidence-based estimations should be used to determine program delivery needs
and resource allocation for PWID in Washington, DC.
Keywords HIV  PWID  Population estimation 
Capture-recapture

Introduction
Since the identification of the HIV/AIDS epidemic in the
District of Columbia (DC), people who inject drugs
(PWID) have borne a disproportionate burden of infection
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risk. The District has seen a 42 % reduction in new cases of
HIV among all risk groups between 2008 and 2012 [1];
injection drug use remains the third leading mode of
transmission overall and PWID are the third largest group
of people living with HIV in DC [1]. Hepatitis C infection
(HCV) is also an issue: between 2008 and 2012, 15,915
new cases of chronic HCV were diagnosed among DC
residents. In the 2010 National Health and Behavior Survey
(NHBS) report on PWID in DC, 90 % of PWID participants indicated they were HCV positive [2].
Existing literature on the size of the PWID population in
DC incorporates the states (or portions of the states) surrounding the District to create a ‘‘metropolitan area’’ estimate. For example, in a 2004 article published by Friedman
et al., the population estimate for DC also included
Maryland, Virginia, and West Virginia and ranged from
5500 to 54,000 [3]. With this estimate including multiple
states and the range being so large, it is hard to determine
how much of the PWID population actually lives in the
District versus elsewhere. This limitation is problematic for
organizations serving PWID in DC because they do not
know the true size of the population they serve.
Health departments and community organizations need
accurate estimates of the size of their target population in
order to adequately allocate resources and ensure sufficient
service provision. Accurate population size estimates are
also useful for mathematical modeling of epidemic impact
of prevention efforts. Capture and recapture methods for
population estimation have been used to estimate the size
of human populations (such as PWID) that are socially
marginalized and often hard to quantify [4–6]. These
studies often base their estimates on community datasets
such as arrests, substance use treatment, or community
based service records. However, these types of source data
are often incomplete due to fringe populations’ lack of trust
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in accessing services unless they are allowed to do so
anonymously. As a result, it is difficult to find two data
sources that can be accurately matched and that represent
the entirety of the population.
At present, DC’s health department has been operating
HIV prevention programs for PWID (such as syringe exchange services) without an evidence-based estimate of the
population size. Implementing a population estimation
study in DC has the potential to offer considerable insights
into the efficacy and reach of syringe exchange program
coverage to PWID. We conducted a capture-recapture
study to develop an accurate estimate of the number of
PWID in DC using a combination of sources, including
data from PWID who are engaging with harm reduction
service providers as well as PWID who are not.

Methods
The capture-recapture study was conducted between March
and April 2014 in accordance with the WHO/UNAIDS
Guidelines on Estimating the Size of Populations Most at
Risk to HIV [10]. We partnered with two local harm reduction service providers who have been engaged in providing services to DC residents since the inception of the
DC Department of Health’s needle exchange network (DC
NEX) in 2008. Together, these two organizations accounted for 98.2 % of the clean injection equipment
(needles and syringes) provided through the DC NEX in
fiscal year 2013. Both organizations provide mobile syringe exchange and one organization provides sterile syringe delivery throughout the city. Both organizations serve
clients in all eight of The District’s wards.
Two 14-day periods of data collection—the capture
phase and the recapture phase—were defined a priori. The
capture phase focused on reaching PWID presenting for
services at either of the two harm reduction organizations.
The recapture phase focused on reaching PWID in the
community who are not engaged with services. In the capture phase, recruitment of study participants occurred during
routine mobile harm reduction outreach. All individuals
presenting for services at mobile syringe exchange locations
or those requesting syringe delivery were given the opportunity to participate. In the recapture phase, community
outreach workers approached individuals in community
locations (e.g., parks, local hangouts, etc.) that were not
connected to or associated with any of the formal syringe
exchange services. Additionally, recapture participants
were recruited through secondary exchange networks,
meaning that they obtained their clean paraphernalia
through other PWID who themselves engaged with syringe
exchange providers and perform bulk distribution of clean
needles to others. By focusing our recapture recruitment on
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community locations and secondary networks, we were able
to access populations of PWID who do not wish or who
cannot engage directly with formal syringe exchange
services.
During both study phases, every individual who was
approached received a verbal description of the study and
was given the chance to ask questions. If they verbally
consented to participate, they completed an anonymous
one-page survey asking questions about individuals’ demographic characteristics, current substance use, and
methods of obtaining clean injection equipment. Small
tokens of appreciation (toiletries kits or new socks) were
given to each individual for their time in completing the
survey. No personally identifying information was collected from participants at any time during the study.
Each token was labeled with a project logo sticker to
allow for easy identification of project participation. Interviewers asked participants if they had already received
one of these tokens before with the project logo sticker.
Those indicating that they had received a token were
categorized as ‘‘recounts’’, meaning that they had been
seen by a study interviewer on more than one occasion
(e.g., initially during the capture phase and again during the
recapture phase).
The study methodology was executed in accordance
with the WHO/UNAIDS Guidelines on Estimating the Size
of Populations Most at Risk to HIV [7]. The mathematical
equation used to estimate the population size and its 95 %
confidence interval are outlined in the WHO/UNAIDS
Guidelines mentioned before. In these equations, necessary
counts include the number of unique PWID identified
during the capture phase, the number of unique PWID in
the recapture phase, and the number of individuals identified during the recapture phase who were also interviewed
during the capture phase.
All completed survey data were entered into a Microsoft
Access database and a 10 % random sample was double
checked for errors. v2 analyses were completed to determine if differences existed between the capture and recapture period PWID on behavioral, syringe access, and
substance use measures. In cases where expected cell
counts were less than 5 for 25 % or more of the cells,
Fisher’s exact test was used. Population estimate mathematical calculations were completed using Microsoft Excel
while all v2 analyses were completed using SAS 9.3.

Results
A total of 951 surveys (244 at capture, 707 at recapture)
were completed during the study. The majority of the
sample was 40 years of age or older (68.2 %), male
(69.8 %), non-Hispanic (76.1 %), African American/Black
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(83.9 %), and residents of DC (90.9 %). Fifty-three percent
of the sample reported having injected drugs in the 30 days
prior to the survey. This number was significantly different
(P \ 0.001) between the capture and recapture phase, with
73.4 % of participant indicating injection drug use in the
capture population versus 49.9 % in the recapture
population. This difference was not surprising given that
the capture phase focused recruitment at local harm reduction organizations while the recapture phase focused on
finding PWID out in the community. There were no other
significant demographic differences observed between the
populations sampled during the capture compared to the
recapture phase.
Residence in the DC was determined by participant reported zip code or state of residence. Overall, DC has 48
residential zip codes; there were 31 unique DC zip codes
reported by participants who indicated IDU in the last
30 days. These zip codes represent all eight wards in the
District. Data pertaining to drug use behaviors of those who
indicated recent injection (overall and by study phase) and
residence in the DC are presented in Table 1. Overall,
PWID reported having initiated their drug use at young
ages, with 62.8 % reporting initiating injection drug use
behavior before the age of 20 and 20.5 % initiating between the ages of 20 and 29. A significant difference was
found in the 40 and older age of injection drug use behavior
initiation category between the capture and recapture
PWID, with significantly more PWID in the capture phase
reporting injection initiation during this time frame (5.0 vs.
1.2 %, P \ .05). When participants were asked to indicate
their injection drug of choice, heroin alone was the most
often cited drug (39.3 %), followed by an equal preference
for using either heroin or cocaine/speedball (19.0 %), and
then cocaine alone (12.6 %). However, significant differences were found in drug of choice between the capture
and recapture PWID categories for cocaine, heroin, and
only hormones/silicone. Significantly more recapture
PWID reported cocaine as their injection drug of choice
(2.9 vs. 16.6 %, P \ .05); however, significantly more
capture PWID reported use of heroin alone (45.7 vs.
36.7 %, P \ .05), or only hormones/silicone (1.4 vs. 0 %,
P \ .05) as their injection drug of choice.
When asked to indicate all the methods used to obtain
clean injection equipment in the last 30 days overall, the
DC NEX was most often reported (55.9 %) followed by
secondary exchange (25.9 %), and purchasing them from
someone else (13.6 %). Capture PWID were also significantly more likely than recapture PWID to have obtained clean syringes by buying them at a pharmacy (8.6
vs. 0.9 %, P \ .05) or getting them through other nonNEX sources (8.6 vs. 0.9 %, P \ .05). Recapture PWID
were significantly more likely than capture PWID to have
obtained clean syringes by purchasing them from another

person (13.6 vs. 18.9 %, P \ .05). Capture PWID were
significantly more likely than recapture PWID to name the
NEX as a preferred source for clean syringes (65.0 vs.
40.5 %, P \ .05).
When participants were asked to indicate what substances they had used the last 90 days, heroin (60.7 %),
alcohol (55.2 %), and cocaine (41.4 %) were the three
most frequently reported substances overall. However,
differences in drugs used were observed for each study
phase. Compared to recapture participants, capture PWID
were significantly more likely to report using amphetamines (5.6 vs. 0.6 %, P \ .05), hallucinogens (7.1 vs. 0.6 %,
P \ .05), heroin (76.4 vs. 54.1 %, P \ .05), and hormones
(3.6 vs. 0.9 %, P \ .05) while recapture PWID were significantly more likely to report using cocaine or crack (35.0
vs. 44.1 %, P \ .05), marijuana (22.1 vs. 33.4 %,
P \ .05), or prescription drugs (7.1 vs. 18.6 %, P \ .05).
To calculate the population estimate using the WHO/
UNAIDS mathematical formula, we calculated [1] the
number of unique PWID interviewed during the capture
period, [2] the number of unique PWID interviewed during
the recapture period, and [3] the number of PWID contacted at both periods. During the capture period, 244 individuals were interviewed however, only 140 (57.4 %) of
these reported injecting during the previous 30 days and
DC as their state of residence; of these, 9 individuals were
identified as being repeat participants (i.e., they had taken
the survey twice during the capture period) and were
therefore removed from the total. This resulted in a total of
131 unique PWID identified during the capture period. Of
the 707 individuals interviewed during the recapture period, 338 (47.8 %) individuals reported injecting drugs in the
previous 30 days. Of these, one survey was removed due to
missing data, leaving a final count of 337 unique PWID
identified in the recapture period. Of these 337 individuals,
5 individuals indicated that they had completed the survey
during both the capture and recapture time periods. Using
these numbers in the equation, 131 capture PWID, 337
recapture PWID, and 5 individuals seen at both time periods, we estimate that there are 8829 (95 % CI 4899 and
12,759) PWID in Washington, DC.

Discussion
Using capture-recapture methodology, we estimate that
there are approximately 9000 PWID in the DC; this number represents approximately 1.8 % of the District’s
500,908 persons aged 18 years and older [8]. A more accurate estimate is important to the District’s HIV and HCV
prevention and control efforts because it provides the
Department of Health and community-based organizations
serving the PWID populations with a better idea of the true
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Table 1 Substance use
behaviors of participants
reporting injection drug use
within 30 days of survey and
DC as residence (N = 478)

All
(n = 478)

Capture
(n = 140)

Recapture
(n = 338)

300 (62.8 %)

80 (57.1 %)

220 (65.1 %)

98 (20.5 %)

29 (20.7 %)

69 (20.4 %)

Age initiated injection drug use
\20
20–29
30–39

30 (6.3 %)

13 (9.3 %)

17 (5.0 %)

40?

11 (2.3 %)

7 (5.0 %)

4 (1.2 %)a

Missing

39 (8.2 %)

11 (7.9 %)

28 (8.3 %)

Cocaine

60 (12.6 %)

4 (2.9 %)

56 (16.6 %)a

Heroin

188 (39.3 %)

64 (45.7 %)

124 (36.7 %)a

Injection drug of choice

Heroin or cocaine/speedball

91 (19.0 %)

22 (15.7 %)

69 (20.4 %)

Only hormones/silicone
PCP

2 (0.4 %)
14 (2.9 %)

2 (1.4 %)
6 (4.3 %)

0a
8 (2.4 %)

Other

84 (17.6 %)

30 (21.4 %)

54 (16.0 %)

Missing

39 (8.2 %)

12 (8.6 %)

27 (8.0 %)

Methods used to obtain clean syringes in last 30 days
NEX

100 (71.4 %)

167 (49.4 %)

Bought at pharmacy

15 (3.1 %)

12 (8.6 %)

3 (0.9 %)a

Bought from person

83 (17.4 %)

19 (13.6 %)

64 (18.9 %)a

3 (2.1 %)

0

Ordered online
Secondary exchange
Other
Missing

267 (55.9 %)

3 (0.6 %)
124 (25.9 %)

53 (37.9 %)

71 (21.0 %)

18 (3.8 %)

12 (8.6 %)

6 (1.8 %)a

126 (26.4 %)

13 (9.3 %)

113 (33.4 %)

91 (65.0 %)

137 (40.5 %)a

2 (1.4 %)

3 (0.9 %)

Preferred method for obtaining clean syringes
NEX
Buy at store or online
Friend or secondary exchange
NEX or friend/secondary
Missing

228 (47.7 %)
5 (1.0 %)
70 (14.6 %)

17 (12.1 %)

53 (15.7 %)

31 (6.5 %)
144 (30.1 %)

10 (7.1 %)
20 (14.3 %)

21 (6.2 %)
124 (36.7 %)

264 (55.2 %)

81 (57.9 %)

183 (54.1 %)

12 (2.5 %)

10 (7.1 %)

2 (0.6 %)a

198 (41.4 %)

49 (35.0 %)

149 (44.1 %)a

7 (5.0 %)

4 (1.2 %)a

107 (76.4 %)

183 (54.1 %)a

Drug(s) used in the last 90 days
Alcohol
Amphetamines
Cocaine or crack
Hallucinogens
Heroin

a

290 (60.7 %)

Hormones/silicone

8 (1.7 %)

5 (3.6 %)

3 (0.9 %)

Inhalants

2 (0.4 %)

0

2 (0.6 %)

Marijuana

144 (30.1 %)

31 (22.1 %)

113 (33.4 %)a

Prescription drugs

73 (15.3 %)

10 (7.1 %)

63 (18.6 %)a

Other

12 (2.5 %)

11 (7.9 %)

1 (0.3 %)a

Missing

32 (6.7 %)

2 (1.4 %)

30 (8.9 %)

v2 test significant at P \ .05 between capture and recapture IDU

size of the client-base for harm reduction services. With
better understanding of the size of the population needing
services, the city can more easily and accurately evaluate
how well the DC NEX and other harm reduction organizations are reaching and serving the population.
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11 (2.3 %)

In an effort to obtain a ‘‘wisdom of the crowd’’ perspective regarding this estimate, we asked our community
harm reduction service provider partners about their
thoughts regarding the accuracy of the estimate based on
their direct experience in serving the PWID community.
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One of the two organizations believed that our 8829 calculation was an overestimate whereas the other organization believed it to be an underestimate. Nonetheless, both
organizations agreed that the true estimate fell within our
95 % confidence interval.
More accurate population estimates allow for appropriate budgeting of resources for the provision of necessary
services and other prevention programming. In 2012, the
World Health Organization (WHO), United Nations Office
on Drug and Crime (UNODC), and UNAIDS released a
technical guide for countries to set targets for universal
access to HIV prevention, treatment and care for injecting
drug users [9]. Among these recommendations was the
determination of adequate syringe coverage given the size
of the PWID population. According to the guidance, coverage can be classified based on the mean number of syringes distributed per PWID into three categories: low (less
than 100), medium (100–200), and high (over 200). Based
on our estimations of the PWID population in the District
and the number of clean syringes distributed by the DC
NEX in fiscal year 2013 (n = 684,000), DC is currently
providing 77.5 syringes per PWID (95 % CI 139.6, 53.6),
which falls into the ‘‘low coverage’’ category. In order to
fall in the middle of the ‘‘medium coverage’’ category, the
DC NEX would need to distribute approximately 1.3 million clean syringes (95 % CI: 735,000, 1.9 million), which
would mean doubling the current amount of syringe distribution. Achieving the goal of medium syringe coverage
has obvious implications for program planning and resource allocation.
Two factors were identified that may have affected the
validity of the IDU population estimate presented in this
manuscript: the use of a 30-day reporting time period for
injection behavior and the ability of this study to access the
most hidden PWID, including new/young injectors and
middle class injectors. Using a 30-day reporting period for
having engaged in injection behavior was done to minimize
recall errors. Research has shown that a shorter 30-day
window versus a longer 6-month window can result in a
15 % reduction in identified population [10]. If we apply
this to our estimate by increasing the number of PWID
identified during each phase, our estimate would increase
from about 9000 to 12,000 individuals. While this is a
substantial increase, it is still within our confidence interval
for the 30-day reporting period estimate.
Another factor that may affect the validity of our estimate was the ability of this study to access the most hidden
segments of this already hard to reach population, such as
the younger or newer PWID or those from higher socioeconomic brackets. We attempted to include all segments of
the PWID population, not just those who engage with the
DC NEX, by recruiting individuals who obtained clean
paraphernalia through secondary exchangers and

individuals who only engaged with community outreach
workers for harm reduction supplies. While these methods
were intended to minimize missed segments of the broader
PWID population, it is possible that there are still subpopulations of PWID who are not engaged with any harm
reduction services and, therefore, would not be seeing
secondary exchangers or community outreach workers.
There were also time and financial constraints associated
with attempting to reach these subpopulations. Further,
given that we only included in our analyses individuals who
explicitly indicated that they were DC residents, our estimate does not reflect the individuals who may actually
reside in DC but who were not comfortable providing their
zip code of residence (11.5 % of the injectors surveyed in
our study) or who reside outside the District but who come
to the city for services (5 % of the injectors surveyed). Had
these uncounted and non-resident individuals been included
in the calculations, our population estimate increases to
approximately 12,000 injectors (95 % CI 7000, 16,500).
Given these limitations and considerations, we recommend
that the population estimate of approximately 9000 be
viewed in the context of being contained within the 95 %
confidence interval, which would accommodate the possible missed populations of PWID who were not accessed.
In examining the population sampled for this study,
some significant differences were identified between the
capture and recapture groups in terms of their substance
use behaviors and harm reduction practices. While heroin
was the most often reported injection drug of choice for
both groups, there were significantly more cocaine injectors in our recapture group. Given that our recapture group
was from the community rather than from syringe exchange sites, it is possible that the sites are not adequately
reaching stimulant injectors with harm reduction services.
More efforts should be undertaken to better understand the
particular needs of stimulant injectors and how harm reduction providers can more successfully engage them.
With regard to harm reduction behaviors, those in the
capture group were more likely to indicate more than one
method of obtaining clean syringes in the past 30 days
compared to those in the recapture group. This finding may
indicate that those who engage with the NEX already prioritize the importance of having clean injection equipment.
It may also indicate how well harm reduction service
providers in the DC NEX emphasize the importance of
clean needle and syringe use, as well as educate clients on
different options for obtaining clean equipment. Such information and education may not be available to those who
choose to not engage with the NEX.
Additionally, we found that while injectors report having initiated injection practices at younger ages (e.g., in
their 20s), they are engaging in needle exchange services
when they are much older (e.g., in their 40s). While this
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finding may be an artifact of simply having an older PWID
population in the District, it also points to the possibility
that young injectors in DC and adjacent areas who are at
the start of their substance use careers are not aware of the
harm reduction services that are available to them and,
therefore, are not accessing services. More research is
needed to better understand the diversity of the substance
using population in the DC area so that efforts can be made
to reach and engage younger populations with harm reduction information and services, including overdose
prevention.
One of the greatest strengths of this study is that we
were able to engage local harm reduction service providers
as collaborators. Their expertise and trust within the PWID
population allowed us access to a population that is often
wary of outsiders, particularly researchers. Also, we were
able to work with our community partners in a manner that
did not disrupt their normal routines for service provision
to PWID clients. This successful collaboration demonstrates that community based organizations, even those
with little experience with research, can be active and
valuable partners as long as researchers respect their needs
and do not jeopardize or detract from their mission of
service provision. When the terms of engagement are based
in respect, the collaboration between research and practice
can be mutually beneficial.
This study provides an evidence-based estimation of the
number of PWID in DC. These data are useful in that they
provide better information for harm reduction service
providers to estimate program delivery needs. With more
accurate population estimates guiding the resource allocation and program implementation, DC’s harm reduction
providers will have greater capacity to meet the needs of
the approximately 9000 PWID at disproportionate risk for
HIV and HCV.
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